Skip to main content

National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report.

Publication ,  Journal Article
Granger, CB; Van Eyk, JE; Mockrin, SC; Anderson, NL; National Heart, Lung, And Blood Institute Clinical Proteomics Working Group
Published in: Circulation
April 13, 2004

The National Heart, Lung, and Blood Institute (NHLBI) Clinical Proteomics Working Group was charged with identifying opportunities and challenges in clinical proteomics and using these as a basis for recommendations aimed at directly improving patient care. The group included representatives of clinical and translational research, proteomic technologies, laboratory medicine, bioinformatics, and 2 of the NHLBI Proteomics Centers, which form part of a program focused on innovative technology development. This report represents the results from a one-and-a-half-day meeting on May 8 and 9, 2003. For the purposes of this report, clinical proteomics is defined as the systematic, comprehensive, large-scale identification of protein patterns ("fingerprints") of disease and the application of this knowledge to improve patient care and public health through better assessment of disease susceptibility, prevention of disease, selection of therapy for the individual, and monitoring of treatment response.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

April 13, 2004

Volume

109

Issue

14

Start / End Page

1697 / 1703

Location

United States

Related Subject Headings

  • United States
  • Risk
  • Research
  • Proteomics
  • Private Sector
  • Patents as Topic
  • National Institutes of Health (U.S.)
  • Male
  • Humans
  • Genetic Predisposition to Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Granger, C. B., Van Eyk, J. E., Mockrin, S. C., Anderson, N. L., & National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. (2004). National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation, 109(14), 1697–1703. https://doi.org/10.1161/01.CIR.0000121563.47232.2A
Granger, Christopher B., Jennifer E. Van Eyk, Stephen C. Mockrin, N Leigh Anderson, and National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. “National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report.Circulation 109, no. 14 (April 13, 2004): 1697–1703. https://doi.org/10.1161/01.CIR.0000121563.47232.2A.
Granger CB, Van Eyk JE, Mockrin SC, Anderson NL, National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation. 2004 Apr 13;109(14):1697–703.
Granger, Christopher B., et al. “National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report.Circulation, vol. 109, no. 14, Apr. 2004, pp. 1697–703. Pubmed, doi:10.1161/01.CIR.0000121563.47232.2A.
Granger CB, Van Eyk JE, Mockrin SC, Anderson NL, National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation. 2004 Apr 13;109(14):1697–1703.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

April 13, 2004

Volume

109

Issue

14

Start / End Page

1697 / 1703

Location

United States

Related Subject Headings

  • United States
  • Risk
  • Research
  • Proteomics
  • Private Sector
  • Patents as Topic
  • National Institutes of Health (U.S.)
  • Male
  • Humans
  • Genetic Predisposition to Disease